Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Therapeutic index:
Relvar Ellipta is indicated for the maintenance treatment of asthma.
Dosage:
The recommended dose of Relvar Ellipta is:
One inhalation of Relvar Ellipta 100/25 micrograms once daily or
One inhalation of Relvar Ellipta 200/25 micrograms once daily
Safety Information:
Contraindications: Relvar Ellipta is contraindicated in patients with severe milk-protein allergy or who have demonstrated hypersensitivity to either fluticasone furoate, vilanterol or any of the excipients.
Warnings and Precautions:
Exacerbations:
Relvar Ellipta should not be used to treat acute asthma symptoms or an acute exacerbation in COPD, for which a short-acting bronchodilator is required. Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.
Adverse Reactions: Very common: Headache, Nasopharyngitis.
Relvar Ellipta was developed in collaboration with INNOVIVA
Trade marks are owned by or licensed to the GSK group of companies.
©2021 GSK group of companies or its licensor.
